Could Amicus Therapeutics, Inc. (FOLD) See a Reversal After Breaking Its 52-Week High?

June 20, 2017 - By Winifred Garcia

Investors sentiment decreased to 1.24 in 2016 Q4. Its down 0.25, from 1.49 in 2016Q3. It turned negative, as 27 investors sold Amicus Therapeutics, Inc. shares while 32 reduced holdings. 25 funds opened positions while 48 raised stakes. 151.10 million shares or 5.89% more from 142.70 million shares in 2016Q3 were reported.
The Colorado-based Janus Cap Mngmt Ltd has invested 0.03% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). 27,732 are owned by Employees Retirement Association Of Colorado. Axa holds 0.05% or 2.17 million shares in its portfolio. Bnp Paribas Arbitrage reported 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Susquehanna Gp Limited Liability Partnership reported 40,473 shares. Sg Americas Securities Ltd Liability Corporation holds 0% or 58,433 shares in its portfolio. Element Cap Mgmt Ltd Liability reported 664,116 shares. Blackrock Gru Limited accumulated 83,733 shares. 4.08M were accumulated by Victory Capital Mngmt Inc. Paloma Prtnrs reported 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Berson & Corrado Investment Advsr Ltd Co accumulated 40,700 shares. 1.13M were accumulated by Deutsche Commercial Bank Ag. The New York-based Amalgamated Savings Bank has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Nj State Employees Deferred Compensation Plan reported 15,000 shares. The California-based Franklin Res has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Since December 22, 2016, it had 3 buys, and 6 selling transactions for $101,704 activity. The insider PERCEPTIVE ADVISORS LLC bought $410,050. 29,914 shares were sold by Do Hung, worth $239,312. Campbell Bradley L sold $392,400 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Thursday, March 2. 30,000 shares were sold by Barth Jay, worth $300,000 on Thursday, June 15.

The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) hit a new 52-week high and has $10.22 target or 4.00 % above today’s $9.83 share price. The 6 months bullish chart indicates low risk for the $1.47 billion company. The 1-year high was reported on Jun, 20 by Barchart.com. If the $10.22 price target is reached, the company will be worth $58.80M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

About 2.02M shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since June 20, 2016 and is uptrending. It has underperformed by 4.25% the S&P500.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Among 7 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Amicus Therapeutics had 12 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was initiated by Robert W. Baird on Thursday, April 14 with “Neutral”. As per Tuesday, September 1, the company rating was maintained by Cowen & Co. The firm has “Buy” rating by Chardan Capital Markets given on Monday, October 5. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Outperform” rating by Robert W. Baird on Tuesday, January 24. The rating was maintained by Leerink Swann on Monday, October 5 with “Outperform”. The firm earned “Buy” rating on Monday, August 31 by Leerink Swann. Bank of America initiated Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Wednesday, May 18 with “Buy” rating. The firm has “Buy” rating by Janney Capital given on Tuesday, March 8. On Tuesday, August 18 the stock rating was downgraded by Zacks to “Buy”. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Neutral” rating by Chardan Capital Markets on Wednesday, September 16.

More notable recent Amicus Therapeutics, Inc. (NASDAQ:FOLD) news were published by: Seekingalpha.com which released: “Amicus Therapeutics: A Rare Find In Biotechnology” on May 24, 2017, also Globenewswire.com with their article: “Amicus Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare …” published on May 31, 2017, Zacks.com published: “Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 7.3%” on June 19, 2017. More interesting news about Amicus Therapeutics, Inc. (NASDAQ:FOLD) were released by: Prnewswire.com and their article: “Breakfast Technical Briefing on Biotech Stocks — CEL-SCI, Amicus Therapeutics …” published on June 12, 2017 as well as Seekingalpha.com‘s news article titled: “New Data Validate Amicus’s Pompe Disease Candidate” with publication date: June 16, 2017.

Amicus Therapeutics, Inc. is a biotechnology company. The company has market cap of $1.47 billion. The Firm is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. It currently has negative earnings. The Company’s lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for Fabry disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.